NCT05491785View on ClinicalTrials.gov

Cebranopadol Effects on Ventilatory Drive, Central Nervous System (CNS) and Pain.

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 29, 2022

Primary Completion Date

March 30, 2023

Study Completion Date

January 2, 2024

Conditions
Pain
Interventions
DRUG

Cebranopadol 600 µg

Participants will be administered a single dose of 8 identically appearing capsules containing: 3 oxycodone placebo capsules, 3 cebranopadol 200 µg tablets and 2 cebranopadol placebo tablets

DRUG

Cebranopadol 800 µg

Participants will be administered a single dose of 8 identically appearing capsules containing: 3 oxycodone placebo capsules, 4 cebranopadol 200 µg tablets and 1 cebranopadol placebo tablet

DRUG

Cebranopadol 1000 µg

Participants will be administered a single dose of 8 identically appearing capsules containing: 3 oxycodone placebo capsules, and 5 cebranopadol 200 µg tablets

DRUG

Oxycodone 30 mg

Participants will be administered a single dose of 8 identically appearing capsules containing: 3 oxycodone 10 mg capsules, and 5 cebranopadol placebo tablets

DRUG

Oxycodone 60 mg

Participants will be administered a single dose of 8 identically appearing capsules containing: 3 oxycodone 20 mg capsules, and 5 cebranopadol placebo tablets

DRUG

Placebo

Participants will be administered a single dose of 8 identically appearing capsules containing: 3 oxycodone placebo capsules, and 5 cebranopadol placebo tablets

Trial Locations (2)

Unknown

Centre for Human Drug Research (CHDR), Leiden

Leiden University Medical Centre (LUMC), Leiden

All Listed Sponsors
lead

Tris Pharma, Inc.

INDUSTRY